Abstract
Malignant solid tumors have been traditionally treated utilizing cytotoxic chemotherapies, which work against rapidly multiplying tumors. The current response evaluation in solid tumor is based on the Response Evaluation Criteria in Solid Tumors (RECIST). This method relies mainly on computerized tomography (CT scans) and other imaging modalities by which the diameter of tumors is taken into consideration to assess response to therapy. Recent years have witnessed the introduction of a series of new signal transduction inhibitors in the management of metastatic RCC. Stable disease (SD) is more frequently seen with morphologic lesion changes such as, change in attenuation, pattern of intratumoral enhancement / necrosis and cavitation, all of which pose a challenge for the investigator in the accurate assessment of response to therapy. This article attempts to introduce the reader to various alternate concepts of monitoring response following biologic therapy and offers a detailed analysis of a few lesions.
Keywords: Renal cell carcinoma, response evaluation, radiological evaluation, functional imaging
Reviews on Recent Clinical Trials
Title: Stable Disease in Renal Cell Carcinoma After Using Signal Transduction Inhibitors
Volume: 5 Issue: 2
Author(s): Saby George, Shetal N. Shah and Ronald M. Bukowski
Affiliation:
Keywords: Renal cell carcinoma, response evaluation, radiological evaluation, functional imaging
Abstract: Malignant solid tumors have been traditionally treated utilizing cytotoxic chemotherapies, which work against rapidly multiplying tumors. The current response evaluation in solid tumor is based on the Response Evaluation Criteria in Solid Tumors (RECIST). This method relies mainly on computerized tomography (CT scans) and other imaging modalities by which the diameter of tumors is taken into consideration to assess response to therapy. Recent years have witnessed the introduction of a series of new signal transduction inhibitors in the management of metastatic RCC. Stable disease (SD) is more frequently seen with morphologic lesion changes such as, change in attenuation, pattern of intratumoral enhancement / necrosis and cavitation, all of which pose a challenge for the investigator in the accurate assessment of response to therapy. This article attempts to introduce the reader to various alternate concepts of monitoring response following biologic therapy and offers a detailed analysis of a few lesions.
Export Options
About this article
Cite this article as:
George Saby, N. Shah Shetal and M. Bukowski Ronald, Stable Disease in Renal Cell Carcinoma After Using Signal Transduction Inhibitors, Reviews on Recent Clinical Trials 2010; 5 (2) . https://dx.doi.org/10.2174/157488710791233635
DOI https://dx.doi.org/10.2174/157488710791233635 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
EGFR-Targeted Therapy in Malignant Glioma: Novel Aspects and Mechanisms of Drug Resistance
Current Molecular Pharmacology Antagonizing IL-6 in Ankylosing Spondylitis: A Short Review
Inflammation & Allergy - Drug Targets (Discontinued) Vascular Endothelial Growth Factor Receptor 1, a Therapeutic Target in Cancer, Inflammation and Other Disorders
Current Medicinal Chemistry Small Molecule Inhibitors of NF-κB and JAK/STAT Signal Transduction Pathways as Promising Anti-Inflammatory Therapeutics
Mini-Reviews in Medicinal Chemistry Matching Chelators to Radiometals for Positron Emission Tomography Imaging- Guided Targeted Drug Delivery
Current Drug Targets Green Synthesis of Silver Nanocomposites of Nigella sativa Seeds Extract for Hepatocellular Carcinoma
Current Nanomaterials Drug-induced Inhibition and Trafficking Disruption of ion Channels: Pathogenesis of QT Abnormalities and Drug-induced Fatal Arrhythmias
Current Cardiology Reviews Processed Foods, Dysbiosis, Systemic Inflammation, and Poor Health
Current Nutrition & Food Science Emerging Concepts on Inhibitors of Indoleamine 2,3-Dioxygenase in Rheumatic Diseases
Current Medicinal Chemistry Editorial (Mini-Thematic Issue: Morphological and Molecular Backgrounds for Personalized Therapies in Genitourinary Cancers)
Current Drug Targets Study of Splicing Factor, Proline- and Glutamine-rich by Proteomic Techniques in Human Malignant and Nonmalignant Cell Lines
Protein & Peptide Letters Preclinical Models to Study Breast Cancer
Clinical Cancer Drugs Advancements within Modern Machine Learning Methodology: Impacts and Prospects in Biomarker Discovery
Current Medicinal Chemistry Carbonic Anhydrase IX as a Target for Designing Novel Anticancer Drugs
Current Medicinal Chemistry Molecular and Clinical Aspects of the Target Therapy with the Calcimimetic Cinacalcet in the Treatment of Parathyroid Tumors
Current Cancer Drug Targets Targeting Cancer Stem Cells: Promises and Challenges
Anti-Cancer Agents in Medicinal Chemistry Back to the Future: COX-2 Inhibitors for Chemoprevention and Cancer Therapy
Mini-Reviews in Medicinal Chemistry Inhalable Antibiotic Nanoformulations for the Treatment of Pseudomonas Aeruginosa Infection in Cystic Fibrosis – A Review
Drug Delivery Letters Sirtuin Modulators: Mechanisms and Potential Clinical Implications
Current Medicinal Chemistry Ocular Inflammatory Diseases: Molecular Pathogenesis and Immunotherapy
Current Molecular Medicine